Can extending rituximab therapy keep vasculitis away longer?

This study looks at whether giving rituximab for a longer time (46 months) can better prevent relapses of ANCA-associated vasculitis compared to the usual shorter treatment (18 months). About 97 adults who are already in remission after initial rituximab therapy will be randomly assigned to receive either continued rituximab or a placebo. The goal is to see if extended treatment keeps the disease under control longer without increasing side effects.